Recruiting

Testing a new drug to reduce seizures in people with hard-to-treat epilepsy

Plain-English translation of NCT07095933 on ClinicalTrials.gov ↗ · Source last updated April 2026 · Translation generated June 2026 · How we translate trials

Read our Epilepsy research guide →

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

What is this trial?

This is a small early-stage study testing whether can help people with focal seizures that haven't been controlled by standard epilepsy drugs. Researchers believe this medication works by interrupting a brain process that seems to "remember" and repeat seizure patterns. The study will look at whether taking this medication is safe and whether it reduces seizure activity when given as an add-on to existing epilepsy treatments.

Many people with epilepsy continue to have seizures even after trying multiple standard medications. This trial explores a completely new approach—using this medication to interfere with the brain's "memory" of seizures shortly after they happen, which could break the cycle of repeated seizures and help people who have run out of other options.

Do you qualify?

You likely qualify if…

you are between 18 and 60 years old
you have been diagnosed with focal seizures (seizures that start in one area of the brain) that have caused loss of awareness
you have had at least 16 seizures in the 8 weeks before enrollment and have not gone seizure-free for 21 consecutive days
you have drug-resistant epilepsy, meaning at least two standard anti-seizure medications have not worked for you despite being used at proper doses for at least 2 years
you have had imaging tests (MRI or CT scan) or brain wave recordings (EEG) within the past 2 years that confirm focal epilepsy

You likely don't qualify if…

you have primary generalized epilepsy (seizures that start across the whole brain at once)
you have had non-epileptic seizures or psychogenic non-epileptic events
you have had status epilepticus (very long or repeated seizures without recovery) or seizure clusters within the past 12 months
you are already taking or have recently taken other mTOR inhibitors (within the past 12 months)
you have serious uncontrolled medical conditions such as liver or kidney disease, active infections, or advanced cancer

What participation looks like

You would take the study medication as a pill in addition to your current epilepsy drugs. The study is very small (only about 5 participants) and is in its earliest testing phase, so the duration and exact visit schedule are not fully detailed in this record, but you would need to keep detailed records of your seizures, attend regular study visits, have brain wave monitoring, and follow all study instructions. Throughout the trial, researchers will monitor whether the medication is safe and whether your seizures decrease.

AI-generated summary from trial data · Jun 1, 2026 · Not medical advice

Trial locations(1 site)

China

Xuanwu Hospital, Beijing, Beijing, Beijing Municipality